Principal Investigators (Canada)

 Dr. Niall Ferguson 

Dr. Fran├žois Lamontagne


 Principal Investigators (USA)
 Dr. Derek C. Angus
 Dr. Marc Moss

Thanks to the CCCTG and the PETAL Network endorsing this research project.
  • Upcoming PETAL Session
    March 2016: ROSE Trial to be featured at Upcoming PETAL Network Session at American Thoracic Society International Conference, San Francisco, CA (May 13 to 16, 2016).
  • ROSE Trial Opens in US
    Feb. 2016: ROSE Trial Opens in US PETAL Network Sites in January 2016 - 21 patients enrolled in 1st month!
  • NIH Review Committee
    Feb. 2015: The ROSE trial was approved by the NIH Protocol Review Committee and will enrol patients beginning in 2016.

The ROSE Program

Neuromuscular blocking agents are medications that paralyze muscles. In 2010 a relatively small study conducted in France suggested that these paralytics improved the survival of patients suffering from a life-threatening form of respiratory failure. If the results of this study are true, paralytic agents are the first drug to improve survival of patients with this syndrome.

However, these results are uncertain and require confirmation considering that paralytics may cause significant weakness and compromise the survivors' functional autonomy and quality of life. The current proposal means to assess the benefits and risks associated with neuromuscular blocking agents administered to patients with life-threatening respiratory failure, and determine if they really save lives.

 If you are interested in joining this program of research please

Our primary research question and hypothesis

What is the effect of early neuromuscular blockade therapy versus usual care without neuromuscular blockade, on all-cause hospital mortality among patients with moderate-severe early ARDS? We hypothesize that use of neuromuscular blocking agents will reduce mortality by 15-20% in this population.

Learn more about ARDS

Read more about this devastating illness which kills hundreds of thousands every year. The impact of ARDS goes well beyond the lives it claims. Survivors often suffer from long term complications, some of which may be caused by medical  interventions.

Learn about the patients' perspectives